United States Diabetes Care Drugs and Devices Market Size - Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

United States Diabetes Care Drugs and Devices Market Overview

Diabetes care drugs and devices play a critical role in managing blood glucose levels, preventing complications, and improving the quality of life for patients. Key products include insulin therapies, oral antidiabetic drugs, continuous glucose monitors, insulin pumps, and other advanced monitoring systems. The diabetes care drugs and devices market in the United States is highly dynamic, driven by rising diabetes prevalence, technological advancements, and increasing patient awareness. The market is poised to grow at a CAGR of 2.70% during the forecast period of 2026-2035, with significant opportunities in innovative therapies, digital health integration, and improved treatment accessibility.

United States Diabetes Care Drugs and Devices Market Growth Driver

Increasing Expansion of GLP-1 Therapies to Drive the Market Value

The increasing availability of generic GLP-1 receptor agonists is a key growth driver in the market. For instance, in June 2024, Teva Pharmaceuticals launched an authorized generic of Victoza® (liraglutide injection 1.8 mg), the first generic GLP-1 therapy in the U.S. This launch enhances treatment accessibility for adults and pediatric patients with type 2 diabetes while supporting cardiovascular risk reduction. By addressing rising demand for effective and affordable therapies, such developments are expected to bolster market adoption, expand patient options, and drive sustained growth in the diabetes care sector.

United States Diabetes Care Drugs and Devices Market Trends

The market is experiencing key trends, including the increasing development of interchangeable biosimilar insulins and the growing adoption of rapid-acting insulin biosimilars

Rising Development of Interchangeable Biosimilar Insulins to Boost the Market Growth in the United States

The market is witnessing a significant trend toward the introduction of interchangeable biosimilar insulins, enhancing treatment accessibility and affordability. In July 2025, Biocon Biologics received FDA approval for Kirsty™, the first and only interchangeable rapid-acting insulin aspart in the U.S., complementing its existing Semglee® portfolio. This milestone underscores a growing focus on patient-centric innovation and biosimilar adoption, providing clinicians and patients with more flexible therapeutic options. Such advancements are expected to drive market expansion by improving insulin availability and supporting better glycemic management across the diabetic population.

Growing Adoption of Rapid-Acting Insulin Biosimilars is Likely to Enhance the Diabetes Care Drugs and Devices Market Landscape

The increased adoption of biosimilar insulin products, particularly rapid-acting formulations, to improve patient access and affordability, is a key trend shaping the market. In February 2025, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) by Sanofi-Aventis U.S. LLC, marking the first rapid-acting insulin biosimilar available for both adult and pediatric patients. This approval highlights ongoing efforts to expand competitive treatment options and enhance glycemic control for millions relying on insulin therapy. Such developments are expected to strengthen market growth by broadening treatment accessibility and supporting cost-effective diabetes management.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

United States Diabetes Care Drugs and Devices Market Share

Devices Expected to Lead the Market Share by Product Type

The market is primarily segmented into two major product types, including devices and drugs. Among these, devices including insulin pumps, insulin syringes, etc., are expected to hold a significant share in the market, due to the increasing adoption of advanced diabetes management technologies. For instance, in August 2024, the FDA clearance of Insulet SmartAdjust technology for adults with type 2 diabetes exemplifies this trend, providing automated insulin dosing and reducing the daily burden of disease management. This regulatory support and technological innovation are poised to drive significant device adoption, enhancing patient outcomes and quality of life.

Leading Players in the United States Diabetes Care Drugs and Devices Market

Other key players in the market include Novartis AG, Eli Lilly and Company, F. Hoffmann La Roche, AstraZeneca plc, Pfizer Inc., and Dexcom.

United States Diabetes Care Drugs and Devices Market Segmentation

Key Questions Answered in the United States Diabetes Care Drugs and Devices Market Report

• What was the United States diabetes care drugs and devices market value in 2025?
• What is the United States diabetes care drugs and devices market forecast outlook for 2026-2035?
• What are the major factors aiding the United States diabetes care drugs and devices market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major United States diabetes care drugs and devices market trends?
• Which disease type is expected to dominate the market segment?
• Which product type is projected to lead the market segment?
• Which distribution channel is anticipated to drive the market segment?
• Which end user is likely to dominate the market segment?
• Who are the key players involved in the United States diabetes care drugs and devices market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?